Display options
Cite
Kim M, Kim BH. Current Guidelines for Management of Medullary Thyroid Carcinoma. Endocrinol Metab (Seoul). 2021;36(3):514-524doi: 10.3803/EnM.2021.1082.
Kim, M., & Kim, B. H. (2021). Current Guidelines for Management of Medullary Thyroid Carcinoma. Endocrinology and metabolism (Seoul, Korea), 36(3), 514-524. https://doi.org/10.3803/EnM.2021.1082
Kim, Mijin, and Kim, Bo Hyun. "Current Guidelines for Management of Medullary Thyroid Carcinoma." Endocrinology and metabolism (Seoul, Korea) vol. 36,3 (2021): 514-524. doi: https://doi.org/10.3803/EnM.2021.1082
Kim M, Kim BH. Current Guidelines for Management of Medullary Thyroid Carcinoma. Endocrinol Metab (Seoul). 2021 Jun;36(3):514-524. doi: 10.3803/EnM.2021.1082. Epub 2021 Jun 22. PMID: 34154310; PMCID: PMC8258323.
Copy Download .nbib Format: NLM
Share it on

Endocrinol Metab (Seoul). 2021 Jun;36(3):514-524. doi: 10.3803/EnM.2021.1082. Epub 2021 Jun 22.

Current Guidelines for Management of Medullary Thyroid Carcinoma.

Endocrinology and metabolism (Seoul, Korea)

Mijin Kim, Bo Hyun Kim

Affiliations

  1. Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.

PMID: 34154310 PMCID: PMC8258323 DOI: 10.3803/EnM.2021.1082

Abstract

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from the parafollicular cells. The diagnostic and therapeutic strategies for the condition are different from those used for well-differentiated thyroid cancer. Since the 2015 American Thyroid Association guidelines for the diagnosis and treatment of MTC, the latest, including the National Comprehensive Cancer Network and European Association for Medical Oncology guidelines have been updated to reflect several recent advances in the management of MTC. Advances in molecular diagnosis and postoperative risk stratification systems have led to individualized treatment and follow-up strategies. Multi-kinase inhibitors, such as vandetanib and cabozantinib, can prolong disease progression-free survival with favorable adverse effects. In addition, potent selective rearranged during transfection (RET) inhibitors (selpercatinib and pralsetinib) have shown a promising efficacy in recent clinical trials. This review summarizes the management of MTC in recent guidelines focused on sporadic MTC.

Keywords: Cabozantinib; Guidelines; Pralsetinib; Precision medicine; Selpercatinib; Thyroid cancer, medullary

References

  1. Eur J Endocrinol. 2008 Feb;158(2):239-46 - PubMed
  2. Cancer Res Treat. 2015 Jul;47(3):362-9 - PubMed
  3. Endocrine. 2016 Jul;53(1):174-81 - PubMed
  4. J Clin Oncol. 2020 Aug 20;38(24):2773-2781 - PubMed
  5. J Clin Oncol. 2013 Oct 10;31(29):3639-46 - PubMed
  6. Cancer. 1979 Mar;43(3):825-37 - PubMed
  7. Endocrine. 2021 Feb;71(2):434-442 - PubMed
  8. JAMA Surg. 2017 Sep 1;152(9):869-876 - PubMed
  9. Thyroid. 2015 Jun;25(6):567-610 - PubMed
  10. Drugs. 2020 Nov;80(17):1865-1870 - PubMed
  11. J Clin Endocrinol Metab. 2010 Jun;95(6):2655-63 - PubMed
  12. Ann Oncol. 2017 Nov 1;28(11):2813-2819 - PubMed
  13. J Nucl Med. 2006 Feb;47(2):247-55 - PubMed
  14. Horm Metab Res. 2020 Aug;52(8):562-577 - PubMed
  15. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  16. Endocr J. 2020 Jul 28;67(7):669-717 - PubMed
  17. Clin Cancer Res. 2021 Apr 15;27(8):2130-2135 - PubMed
  18. Thyroid. 2015 Feb;25(2):242-9 - PubMed
  19. J Med Genet. 2016 Nov;53(11):729-734 - PubMed
  20. Lancet Oncol. 2020 Oct;21(10):1353-1365 - PubMed
  21. Clin Cancer Res. 2004 May 1;10(9):2944-53 - PubMed
  22. Thyroid. 2021 Mar;31(3):459-469 - PubMed
  23. Clin Cancer Res. 2021 Jul 1;27(13):3567-3575 - PubMed
  24. J Clin Oncol. 2012 Jan 10;30(2):134-41 - PubMed
  25. Hell J Nucl Med. 2015 Jan-Apr;18(1):19-24 - PubMed
  26. Thyroid. 2020 Aug;30(8):1112-1119 - PubMed
  27. Endocrinol Metab (Seoul). 2020 Sep;35(3):587-594 - PubMed
  28. BMC Cancer. 2019 Apr 5;19(1):325 - PubMed
  29. Eur J Cancer. 2017 May;76:110-117 - PubMed
  30. Horm Metab Res. 2008 Feb;40(2):108-16 - PubMed
  31. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6696-702 - PubMed
  32. Ann Oncol. 1994 Oct;5(8):763-5 - PubMed
  33. Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):335-347 - PubMed
  34. Clin Oncol (R Coll Radiol). 2010 Aug;22(6):475-85 - PubMed
  35. Ann Oncol. 2019 Dec 1;30(12):1856-1883 - PubMed
  36. N Engl J Med. 2020 Aug 27;383(9):825-835 - PubMed
  37. J Clin Endocrinol Metab. 2013 May;98(5):E811-9 - PubMed
  38. J Clin Oncol. 2006 Apr 10;24(11):1705-11 - PubMed
  39. Clin Cancer Res. 2016 Jan 1;22(1):44-53 - PubMed
  40. Endocr Relat Cancer. 2017 Nov;24(11):R387-R402 - PubMed
  41. Semin Nucl Med. 2016 May;46(3):215-24 - PubMed
  42. Eur Thyroid J. 2021 Apr;10(2):125-139 - PubMed

Publication Types

Grant support